DrugPipeline.net has announced the addition of “Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017” research report to their website www.DrugPipeline.net

Bangalore, India -- (SBWire) -- 10/06/2017 --Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 6, 5, 18 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 2, 1, 1 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 127 pages "Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017" report covers Introduction, Report Coverage, Influenza A Virus, H3N2 Subtype Infections - Overview, Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development, Pipeline Overview, Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment, Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development, Influenza A Virus, H3N2 Subtype Infections - Drug Profiles, Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, Appendix. This report Covered Companies few are - AbbVie Inc, Adimmune Corp, AIMM Therapeutics BV, Aphios Corp, BioCryst Pharmaceuticals Inc, BiondVax Pharmaceuticals Ltd, Cadila Healthcare Ltd, Celltrion Inc, FluGen Inc, Glide Pharmaceutical Technologies Ltd, Inovio Pharmaceuticals Inc, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson.

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/influenza-virus-h3n2-subtype-infections-pipeline-review-h2-2017

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/juvenile-macular-degeneration-stargardt-disease-pipeline-review-h2-2017

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2017 - Visit at - http://www.drugpipeline.net/global-markets-direct/metabotropic-glutamate-receptor-3-gprc1c-or-mglur3-or-grm3-pipeline-review-0

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.